These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36453228)

  • 41. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.
    Moulton HM; Moulton JD
    Biochim Biophys Acta; 2010 Dec; 1798(12):2296-303. PubMed ID: 20170628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
    Nik-Ahd F; Bertoni C
    Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
    Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.
    Ferrer A; Wells KE; Wells DJ
    Gene Ther; 2000 Sep; 7(17):1439-46. PubMed ID: 11001363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.
    Frank DE; Schnell FJ; Akana C; El-Husayni SH; Desjardins CA; Morgan J; Charleston JS; Sardone V; Domingos J; Dickson G; Straub V; Guglieri M; Mercuri E; Servais L; Muntoni F;
    Neurology; 2020 May; 94(21):e2270-e2282. PubMed ID: 32139505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
    Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
    Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
    Duan D
    Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
    Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
    Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.
    Verhaart IE; Heemskerk H; Karnaoukh TG; Kolfschoten IG; Vroon A; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Hum Gene Ther; 2012 Mar; 23(3):262-73. PubMed ID: 22017442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
    Erkut E; Yokota T
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular characterization of exonic rearrangements and frame shifts in the dystrophin gene in Duchenne muscular dystrophy patients in a Saudi community.
    Elhawary NA; Jiffri EH; Jambi S; Mufti AH; Dannoun A; Kordi H; Khogeer A; Jiffri OH; Elhawary AN; Tayeb MT
    Hum Genomics; 2018 Apr; 12(1):18. PubMed ID: 29631625
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.
    Charleston JS; Schnell FJ; Dworzak J; Donoghue C; Lewis S; Chen L; Young GD; Milici AJ; Voss J; DeAlwis U; Wentworth B; Rodino-Klapac LR; Sahenk Z; Frank D; Mendell JR
    Neurology; 2018 Jun; 90(24):e2146-e2154. PubMed ID: 29752304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy.
    Birch SM; Lawlor MW; Conlon TJ; Guo LJ; Crudele JM; Hawkins EC; Nghiem PP; Ahn M; Meng H; Beatka MJ; Fickau BA; Prieto JC; Styner MA; Struharik MJ; Shanks C; Brown KJ; Golebiowski D; Bettis AK; Balog-Alvarez CJ; Clement N; Coleman KE; Corti M; Pan X; Hauschka SD; Gonzalez JP; Morris CA; Schneider JS; Duan D; Chamberlain JS; Byrne BJ; Kornegay JN
    Sci Transl Med; 2023 Jan; 15(677):eabo1815. PubMed ID: 36599002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD).
    Kawecka K; Theodoulides M; Hasoglu Y; Jarmin S; Kymalainen H; Le-Heron A; Popplewell L; Malerba A; Dickson G; Athanasopoulos T
    Curr Gene Ther; 2015; 15(4):395-415. PubMed ID: 26159373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.
    Shin JH; Pan X; Hakim CH; Yang HT; Yue Y; Zhang K; Terjung RL; Duan D
    Mol Ther; 2013 Apr; 21(4):750-7. PubMed ID: 23319056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.
    Wilton SD; Fletcher S
    Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene editing and modulation for Duchenne muscular dystrophy.
    Stephenson AA; Flanigan KM
    Prog Mol Biol Transl Sci; 2021; 182():225-255. PubMed ID: 34175043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.